LY01011

DRUG2 trials

Sponsors

Luye Pharma Group Ltd.

Conditions

Bone Metastases From Solid TumorsHealthy Adults

Phase 1

A Study to Evaluate LY01011 and Xgeva® in Healthy Adults

Luye Pharma Group Ltd.Healthy Adults

Start: 2019-12-16End: 2021-06-30Target: 168Updated: 2019-12-13

Phase 3

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Luye Pharma Group Ltd.Bone Metastases From Solid Tumors

Start: 2021-04-30End: 2023-06-30Target: 850Updated: 2021-06-07

Related Papers

Denosumab biosimilar (LY01011) in the treatment of bone metastases in patients with solid tumors: A multicenter, randomized, double-blind, active comparator-controlled phase 3 study.

Journal of Clinical Oncology2023-06-01

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

BioDrugs2023-02-2111 citations